Generic name
Lanthanum carbonate: adverse event reports filed with FDA
645 reports list it as a suspect or interacting product, 2006–2026. Class: Phosphate binder.
- 645
- reports as suspect product
- 0% of all reports · about 32 a year
- 89
- reports, 12 months to June 2026
- 74 in the 12 months before
- 97.4%
- marked serious by the reporter
- 49.7% across the class
- 71.6%
- record death among outcomes, as reported
- 462 reports · not verified by FDA
Between April 2006 and June 2026, 645 adverse event reports received by FDA list lanthanum carbonate, a generic name as a suspect or interacting product. Reports that mention it only as a concomitant medication (637) are left out of every figure here.
In the 12 months to June 2026, 89 reports listed it, up 20% from 74 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 32 reports a year and 0% of the 20,646,523 reports in the database, and 5.7% of the reports for the phosphate binder class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded hyponatraemia (38.6%), general physical health deterioration (37.8%) and multiple organ dysfunction syndrome (37.5%). A report can list several reactions, so shares add to more than 100%; 198 different terms appear across these reports. Hyponatraemia is recorded in 38.6% of these reports, with no counterpart in the median phosphate binder drug (0%).
97.4% of the reports are marked serious by the reporter (49.7% across the class); 71.6% record death among the outcomes and 49.9% record hospitalisation, as reported. 60.5% of the reports came from other health professionals, and the largest patient age group is 75 and over (50.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Lanthanum carbonate reports recording the termmedian drug in phosphate binder
- Hyponatraemialow blood sodium38.6%249
- General physical health deteriorationgeneral decline in health37.8%244
- Multiple organ dysfunction syndromeseveral organs failing37.5%242
- Abdominal distensiona bloated abdomen36.7%237
- Sepsisa severe body-wide response to infection36.6%236
- Stressstress36.3%234
- Nauseafeeling sick35.2%227
- Appendicitis35%226
- Vomitingbeing sick35%226
- Abdominal painstomach or belly pain34.9%225
- Ascitesfluid in the abdomen34.9%225
- Appendicolith34.6%223
- Constipationconstipation34%219
- Cardiogenic shockshock from the heart failing to pump33.8%218
- Off label useused for a purpose or in a way not on the label33.5%216
- Ventricular fibrillationa chaotic rhythm from the lower heart chambers32.9%212
- Deaththe patient died; cause not stated by this term29.6%191
- Condition aggravatedthe condition being treated got worse26.5%171
- Somnolencedrowsiness26.4%170
- Blood phosphorus increased23.6%152
- Anaemialow red blood cells22.6%146
- Dry mouthdry mouth22.6%146
- Myasthenia gravis22.3%144
- Incorrect route of product administrationthe product was given by the wrong route21.7%140
- Chronic obstructive pulmonary diseaseCOPD, a long-term lung disease21.2%137
- Diabetes mellitusdiabetes20.6%133
- Bacterial infectiona bacterial infection20.5%132
- Intentional product misusedeliberate use not as intended20.5%132
- Thrombosis20.5%132
- Hyperphosphataemia20.3%131
Top 30 of 198 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 5 drugs in the phosphate binder class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 11,219 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 26.4% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Blood phosphorus increased | 164 | 25.4% |
| Hyperphosphataemia | 131 | 20.3% |
| Off label use | 31 | 4.8% |
| Chronic kidney disease-mineral and bone disorder | 3 | 0.5% |
| Chronic kidney disease | 2 | 0.3% |
| End stage renal disease | 2 | 0.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 645 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Lanthanum carbonate reports |
|---|---|---|
| Allopurinol | 303 | 47% |
| Lansoprazole | 294 | 45.6% |
| Metronidazole | 287 | 44.5% |
| Ondansetron | 281 | 43.6% |
| Gabapentin | 280 | 43.4% |
| Acetaminophen | 275 | 42.6% |
| Melatonin | 271 | 42% |
| Calcitriol | 263 | 40.8% |
| Ipratropium bromide | 261 | 40.5% |
| Dextrose | 259 | 40.2% |
Other products listed in reports where Lanthanum carbonate is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Lanthanum carbonate | Phosphate binder | All reports |
|---|---|---|---|
| Reports as suspect product | 645 | 11,219 | 20,646,523 |
| Share of that pool | — | 5.7% | 0% |
| Reports, latest 12 months | 89 | — | 1,332,454 |
| Marked serious | 97.4% | 49.7% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 716 | 249 | 91 |
| Hospitalisation recorded, per 1,000 reports | 499 | 186 | 213 |
| Consumer-filed share | 28.7% | 26.2% | 45.8% |
| Top term, share of reports | Hyponatraemia 38.6% | median 0% | 0.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the phosphate binder class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Renvela | brand | 5,209 | 18 | 18.4% |
| Velphoro | brand | 2,440 | 77 | 72.9% |
| Fosrenol | brand | 2,159 | 34 | 85.9% |
| Sevelamer carbonate | generic | 766 | 41 | 46.5% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Lanthanum carbonate reports
How many adverse event reports has FDA received for Lanthanum carbonate?
645 reports list Lanthanum carbonate as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 89 of them arrived in the latest 12 months. Another 637 list it only as a concomitant medication.
What reactions are recorded in Lanthanum carbonate reports?
hyponatraemia (38.6%), general physical health deterioration (37.8%), multiple organ dysfunction syndrome (37.5%), abdominal distension (36.7%) and sepsis (36.6%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Lanthanum carbonate was responsible.
How serious are the reports?
97.4% are marked serious by the reporter. Among the outcomes recorded, 71.6% of reports include death and 49.9% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (60.5%), consumer or non-health professional (28.7%) and physician (9.6%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Lanthanum carbonate rising?
89 reports in the 12 months to June 2026, up 20% from 74 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Lanthanum carbonate was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Lanthanum carbonate?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Lanthanum carbonate as a suspect or interacting product; reports listing it only as a concomitant medication (637) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.